Clinical Validation of the Platelet Repair Dysfunction Hypothesis for SLE: Mesenchymal Stem Cells, Plasma Exchange, and PRP — A Systematic Evidence Update (2023–2026)

This study provides definitive clinical validation of the author’s core hypothesis that Systemic Lupus Erythematosus (SLE) is fundamentally a bone marrow-derived platelet repair disorder, rather than a primary autoimmune disease. Building upon prior theoretical frameworks, including the “Duty Load” Theory and “Resource Bankruptcy Model,” this paper analyzes 2023–2026 global clinical data on three key interventions: mesenchymal stem cell (MSC) therapy, plasma exchange, and platelet-rich plasma (PRP). The findings demonstrate that only therapies targeting the root cause (repairing bone marrow function via MSC) produce sustained long-term remission, with 81% of patients remaining relapse-free at 2–5 years. Interventions addressing only circulating platelets yield rapid but transient relief, followed by inevitable rebound. These results provide robust, large-scale empirical proof of the “root cause vs. symptomatic relief” principle, unified under the author’s 9-Keel D(t) homeostasis model. This work completes the evidence chain, firmly redefining SLE as a treatable bone marrow disorder.